On January 27, 2020, the Governmental Accountability Office (GAO) released a report on the Medicaid 340B Drug Discount Program, particularly how the 340B program intersects with the Medicaid Drug Rebate Program. The GAO argued that a lack of transparency and documentation results in Medicaid beneficiaries receive drugs that are subject to both the discounted pricing under 340B and Medicaid rebates. The GAO stressed the need for increased oversight on behalf of the Department of Health and Human Services (HHS) to prevent duplicate discounts.
